Torrent Telmisartan/Hydrochlorothiazide Tablets Recall: Superpotent Risk
Torrent Pharma recalls 40mg/12.5mg Telmisartan and Hydrochlorothiazide tablets due to superpotent hydrochlorothiazide risk. Rx-only bottles with specific NDC and batch numbers affected.
Recall notice
Superpotent; Hydrochlorothiazide
Contact the company
What happened, in plain English
Torrent Pharma recalls 30-count tablets containing Telmisartan and Hydrochlorothiazide for a superpotent hydrochlorothiazide risk. This could cause serious health issues if taken without medical supervision. Read more at govinfonow.com/recall/35500-torrent-telmisartan-hydrochlorothiazide-tablets-recall-superpotent-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/35500-torrent-telmisartan-hydrochlorothiazide-tablets-recall-superpotent-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0285-2022
Cite this page
“Torrent Telmisartan/Hydrochlorothiazide Tablets Recall: Superpotent Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/35500-torrent-telmisartan-hydrochlorothiazide-tablets-recall-superpotent-risk. Based on FDA recall #D-0285-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0285-2022%22&limit=1).
Why it’s dangerous
The hydrochlorothiazide component is described as 'superpotent,' which could lead to serious health effects if taken without proper medical supervision. This medication is prescription-only and requires careful dosing.
Who’s affected
People with prescriptions for these specific tablets. Those who have the NDC 13668-159-30 batch BZ74G001 (expiring Dec 2021) are most at risk.
How to tell if you have this one
Check for 30-count tablets labeled 'Telmisartan and Hydrochlorothiazide Tablets, USP, 40 mg/12.5 mg.' Look for NDC 13668-159-30 and batch BZ74G001 (expiring Dec 2021).
- Brand
Torrent- Category
Drug
What to do — step by step
Check Your Medication
Verify if your prescription contains the specific NDC 13668-159-30 batch BZ74G001 (expiring Dec 2021).
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 2.4 years after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0285-2022 (December 1, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0285-2022 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.